<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0002863'>Myelodysplastic Syndromes</z:hpo> are stem cell <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> disorders characterized by peripheral cytopenias and hypercellular bone marrow, which can evolute to <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="122" ids="21241">Vitamin C</z:chebi> can act as an <z:chebi fb="11" ids="22586">antioxidant</z:chebi>, <z:chebi fb="6" ids="22652,29073">ascorbic acid</z:chebi> (AA) donates two electrons and becomes oxidized to <z:chebi fb="0" ids="17242,27956">dehydroascorbic acid</z:chebi> (DHA) </plain></SENT>
<SENT sid="2" pm="."><plain>Under physiological conditions, <z:chebi fb="122" ids="21241">vitamin C</z:chebi> predominantly exists in its reduced (AA) form but also exists in trace quantities in the oxidized form (DHA) </plain></SENT>
<SENT sid="3" pm="."><plain>This study evaluates the therapeutic potential of <z:chebi fb="122" ids="21241">vitamin C</z:chebi> in <z:hpo ids='HP_0002863'>Myelodysplastic Syndromes</z:hpo> (MDSs) </plain></SENT>
<SENT sid="4" pm="."><plain>F36P cells (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cell line) were treated with <z:chebi fb="0" ids="22651">ascorbate</z:chebi> and dehydroascorbate alone and in combination with <z:chebi fb="0" ids="28680">cytarabine</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Cell proliferation and viability were assessed by trypan blue assay and cell <z:hpo ids='HP_0011420'>death</z:hpo> was evaluated by optical microscopy and flow cytometry </plain></SENT>
<SENT sid="6" pm="."><plain>The role of reactive oxygen species, <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> membrane potential, BAX, BCL-2 and <z:chebi fb="0" ids="4056">cytochrome</z:chebi> C were also assessed </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="122" ids="21241">Vitamin C</z:chebi> decreases cell proliferation and viability in a concentration, time and administration dependent-manner inducing cell <z:hpo ids='HP_0011420'>death</z:hpo> by <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, which was shown to be associated to an increased in <z:chebi fb="1" ids="18421">superoxide</z:chebi> production, <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> membrane depolarization </plain></SENT>
<SENT sid="8" pm="."><plain>These compounds modulate BCL-2, BAX and <z:chebi fb="0" ids="4056">cytochrome</z:chebi> C release </plain></SENT>
<SENT sid="9" pm="."><plain>These results suggest that <z:chebi fb="122" ids="21241">vitamin C</z:chebi> induces cell <z:hpo ids='HP_0011420'>death</z:hpo> trough <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in F36P cells and may be a new therapeutic approach in <z:hpo ids='HP_0002863'>Myelodysplasia</z:hpo> </plain></SENT>
</text></document>